While an in vivo study testing the therapeutic potency of FGF21 in choline-deficient and high-fat diet-induced NASH has previously reported both anti-inflammatory and anti-fibrotic effects (Bao et al., 2018), detailed mechanistic understanding is still lacking. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.